In a report issued today, the Government Accountability Office recommended that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B drug savings program requirements. Requested by Republican leaders of the House Energy and Commerce Committee, the report reviews the use of contract pharmacies in the 340B program. HRSA concurs in the report with GAO recommendations that it issue guidance on preventing duplicate discounts under Medicaid managed care and assess compliance, and issue more specific guidance regarding contract pharmacy oversight. The agency also agreed with a GAO recommendation to issue guidance on the length of time covered entities must look back following an audit to identify the full scope of noncompliance identified during the audit. HRSA disagreed in the report with a GAO recommendation that it require covered entities to register contract pharmacies for each site of the entity for which a contract exists, and with recommendations that audited covered entities provide certain additional information.

Related News Articles

Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…